Our CDH17 trial should trump the results of the 2nd-gen CAR-T technology of Satri-cel. Its a shame that the results garnering just a couple of extra months for patients over SOC or TPC can lay claim to being the first breakthrough in solid tumours in a CAR-T Phase 2 trial.
Headlines such as: "Immunotherapy trial helps cancer patients with tumours live 40% longer. Experts praise groundbreaking results from therapy using genetically modified Car T-cells."
Eventhough they get to lay down fame at this juncture in the solid tumour space, it will attract attention to the field, and hopefully, our 3rd-gen technology is proving to be miles ahead. At the end of the day, that's what will matter here!
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)